OncoMatch/Clinical Trials/NCT06786026
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Is NCT06786026 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including bevacizumab and QL1706 for tnbc, triple negative breast cancer.
Treatment: bevacizumab · QL1706 · Nab paclitaxel — This study is to evaluate the efficacy and safety of QL1706 plus albumin-bound paclitaxel ± bevacizumab in 1L treatment of r/mTNBC
Check if I qualifyExtracted eligibility criteria
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative (negative)
Required: ESR1 negative (negative)
Required: PR (PGR) negative (negative)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelets ≥100×10^9/L; Hemoglobin ≥90 g/L
Kidney function
Serum creatinine ≤1.5×ULN
Liver function
Serum total bilirubin ≤1.5×ULN, if liver metastasis is present, ≤3ULN; ALT and AST ≤2.5×ULN, if liver metastasis is present, ALT and AST ≤5ULN; AKP≤2.5×ULN
Adequate organ function (no blood components or cell growth factor drugs are allowed within 14 days before the first medication): (1) Absolute neutrophil count ≥1.5×10^9/L; (2) Platelets ≥100×10^9/L; (3) Hemoglobin ≥90 g/L; (4) Serum albumin ≥30 g/L; (5) Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, the FT3 and FT4 levels should be examined at the same time. If the FT3 and FT4 levels are normal, you can be included in the group); (6) Serum total bilirubin ≤1.5×ULN，if liver metastasis is present, ≤3ULN; (7) ALT and AST ≤2.5×ULN, if liver metastasis is present, ALT and AST ≤5ULN; (8) AKP≤2.5×ULN; Serum creatinine ≤1.5×ULN; (9) International normalized ratio (INR) ≤1.5 (not receiving anticoagulant therapy).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify